Citadel Advisors Llc Decreased Coherus Biosciences Inc (Call) (NASDAQ:CHRS) Stake By $21.90 Million

August 13, 2018 - By Jack Shaw

Coherus BioSciences, Inc. (NASDAQ:CHRS) LogoInvestors sentiment increased to 1.49 in 2018 Q1. Its up 0.33, from 1.16 in 2017Q4. It improved, as 10 investors sold CHRS shares while 27 reduced holdings. 21 funds opened positions while 34 raised stakes. 51.20 million shares or 4.31% more from 49.09 million shares in 2017Q4 were reported. Pictet Asset Mngmt Limited holds 66,906 shares or 0% of its portfolio. Vanguard Inc reported 2.06M shares. Laurion Cap Lp reported 38,780 shares. D E Shaw And reported 0% of its portfolio in Coherus BioSciences, Inc. (NASDAQ:CHRS). Parallax Volatility Advisers Limited Partnership invested in 0% or 8,514 shares. Quantbot L P has 0% invested in Coherus BioSciences, Inc. (NASDAQ:CHRS). Rhenman Ptnrs Asset Mgmt accumulated 350,000 shares. Barclays Public Lc owns 10,372 shares or 0% of their US portfolio. Morgan Stanley has 195,119 shares for 0% of their portfolio. Deutsche Savings Bank Ag owns 602,970 shares. Parametric Portfolio Assoc Ltd Liability Co holds 0% in Coherus BioSciences, Inc. (NASDAQ:CHRS) or 21,733 shares. Kennedy Management holds 88,680 shares or 0.02% of its portfolio. 218,448 were reported by Wells Fargo And Mn. Federated Incorporated Pa holds 1,511 shares or 0% of its portfolio. Goldman Sachs Grp Inc invested in 0% or 413,757 shares.

Citadel Advisors Llc decreased its stake in Coherus Biosciences Inc (Call) (NASDAQ:CHRS) by 98.73% based on its latest 2018Q2 regulatory filing with the SEC. Citadel Advisors Llc sold 1.68 million shares as the company’s stock rose 49.27% while stock markets declined. The hedge fund held 21,600 shares of the health care company at the end of 2018Q2, valued at $302,000, down from 1.71 million at the end of the previous reported quarter. Citadel Advisors Llc who had been investing in Coherus Biosciences Inc (Call) for a number of months, seems to be less bullish one the $1.26B market cap company. The stock increased 1.33% or $0.25 during the last trading session, reaching $19. About 338,764 shares traded. Coherus BioSciences, Inc. (NASDAQ:CHRS) has declined 24.26% since August 13, 2017 and is downtrending. It has underperformed by 36.83% the S&P500.

Citadel Advisors Llc, which manages about $202.23 billion US Long portfolio, upped its stake in Medical Pptys Trust Inc (NYSE:MPW) by 1.05 million shares to 1.09M shares, valued at $15.24 million in 2018Q2, according to the filing. It also increased its holding in General Mls Inc (NYSE:GIS) by 803,364 shares in the quarter, for a total of 1.08 million shares, and has risen its stake in Valero Energy Corp New (Call) (NYSE:VLO).

Ken Griffin career started in 1986 as a stocks and options trader. Soon he started a convertible bond arbitrage fund. When the market crashed in 1987, he was already rich. Today he is a billionire and manages and Citadel Investment Group is among the world’s largest hedge funds. In 2011 when many hedge funds and CTAs had poor returns, Citadel had returned over 20%, it also returned nearly 25% in 2012 and then 20+% in 2013. Citadel Advisors Llc is a Illinois-based hedge fund that was founded by Ken Griffin. It had more than $142.00 billion assets under management in December, 2014. Citadel Advisors Llc is the 30th largest hedge fund in our database. Taken from Citadel Advisors latest Adv, the fund reported to have 985 full and part-time employees. Among which 872 performing investment advisory and research functions. The hedge fund had between 11-25 clients.

Coherus BioSciences, Inc. (NASDAQ:CHRS) Ratings Coverage

Among 2 analysts covering Coherus Biosciences (NASDAQ:CHRS), 2 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. Coherus Biosciences had 3 analyst reports since March 9, 2018 according to SRatingsIntel. The company was maintained on Monday, May 14 by Maxim Group. Maxim Group maintained Coherus BioSciences, Inc. (NASDAQ:CHRS) rating on Friday, March 9. Maxim Group has “Buy” rating and $15.0 target. On Friday, March 9 the stock rating was maintained by Citigroup with “Buy”.

Coherus BioSciences, Inc., a biosimilar company, develops and commercializes various therapeutic products worldwide. The company has market cap of $1.26 billion. The firm engages in the development of late-stage clinical products, including CHS-1701 pegfilgrastim biosimilar, a granulocyte colony-stimulating factor product candidate; CHS-1420 adalimumab biosimilar, an anti-tumor necrosis factor product candidate; and CHS-0214, an etanercept biosimilar for rheumatoid arthritis and psoriasis. It currently has negative earnings. It is also developing a pipeline of products in therapeutic areas, such as oncology, immunology, and ophthalmology comprising CHS-3351, a ranibizumab biosimilar; and CHS-2020, an aflibercept biosimilar, as well as CHS-131, a small molecule for multiple sclerosis.

More notable recent Coherus BioSciences, Inc. (NASDAQ:CHRS) news were published by: Benzinga.com which released: “The Daily Biotech Pulse: FDA Panel Backs Insmed, Eidos’ Maiden Earnings, Paratek Awaits Adcom Verdict” on August 08, 2018, also Fool.com with their article: “Here’s Why Coherus Biosciences Rose Over 21% Today” published on July 18, 2018, Nasdaq.com published: “Coherus BioSciences to Report Second Quarter 2018 Financial Results on August 8th” on July 24, 2018. More interesting news about Coherus BioSciences, Inc. (NASDAQ:CHRS) were released by: Benzinga.com and their article: “Benzinga’s Daily Biotech Pulse: PTC To Buy Agilis, Zynerba To Offer Shares, Intuitive Surgical’s Strong Q2” published on July 20, 2018 as well as Nasdaq.com‘s news article titled: “Coherus BioSciences Receives Positive CHMP Opinion for UDENYCAâ„¢ (Pegfilgrastim Biosimilar Candidate)” with publication date: July 27, 2018.

Coherus BioSciences, Inc. (NASDAQ:CHRS) Ratings Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.